Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study

BACKGROUND: Long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) has proven efficacious in randomized controlled trials. Further research is critical to evaluate its effectiveness in real-world settings and identify effective implementation approaches, especially among you...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinsztejn, Beatriz, Torres, Thiago Silva, Hoagland, Brenda, Jalil, Emilia Moreira, Moreira, Ronaldo Ismerio, O'Malley, Gabrielle, Shade, Starley B, Benedetti, Marcos R, Moreira, Julio, Simpson, Keila, Pimenta, Maria Cristina, Veloso, Valdiléa Gonçalves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157454/
https://www.ncbi.nlm.nih.gov/pubmed/37074775
http://dx.doi.org/10.2196/44961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157454/
https://www.ncbi.nlm.nih.gov/pubmed/37074775
http://dx.doi.org/10.2196/44961

Ejemplares similares